



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
08/462,703	06/05/95	HODGEN	G SCH1309-C1

HM42/0609
MILLEN WHITE ZELANO AND BRANIGAN
ARLINGTON COURTHOUSE PLAZA I
SUITE 1400
2200 CLARENDON BOULEVARD
ARLINGTON VA 22201

EXAMINER
JORDAN, K

ART UNIT	PAPER NUMBER
1614	

DATE MAILED: 06/09/98

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.
08/462,703

Applicant(s)
Hodgen et al.

Examiner
Kimberly Jordan

Group Art Unit
1614



☒ Responsive to communication(s) filed on Apr 17, 1998

☐ This action is **FINAL**.

☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire three month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

☒ Claim(s) 42-107 is/are pending in the application.

Of the above, claim(s) _____ is/are withdrawn from consideration.

☐ Claim(s) _____ is/are allowed.

☒ Claim(s) 42-107 is/are rejected.

☐ Claim(s) _____ is/are objected to.

☐ Claims _____ are subject to restriction or election requirement.

Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on _____ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on _____ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been
☐ received.

☐ received in Application No. (Series Code/Serial Number) _____.

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

☐ Notice of References Cited, PTO-892

☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). _____

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

Kim J
KIMBERLY JORDAN
PRIMARY EXAMINER
GROUP 1200

610

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Art Unit: 1205

Claims 42-107 are pending in this application.

The amendment received on April 17, 1998 has been entered.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103© and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

Claims 42-55 and 102-107 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hodgen (AW) in view of Black (A). The claims appear to be drawn to compositions and methods of contraception achieved by administering estrogen and/or progestin and an antiprogestin. Hodgen discloses that estrogen-progestin combinations are currently available (see page 66, middle column, last paragraph). Hodgen also discloses that the antiprogestin RU 486 may be useful as an ovulation inhibiting contraceptive (see page 66, first column - middle column). The claims differ from the cited reference in claiming the combination of estrogen-progestin regimens

Art Unit: 1205

with an antiprogestin as well as progestin only regimens with an antiprogestin. To combine an estrogen-progestin regimen with an antiprogestin would have been obvious as both are known as contraceptives and the combination would also be expected to have a contraceptive effect. To combine a progestin only regimen with an antiprogestin would have been obvious in view of Black which teaches a progestin only contraceptive (see abstract) and because as stated above it is obvious to combine two contraceptives to be used together for a contraceptive purpose. The claims fail to patentably distinguish over the state of the art as represented by the cited references.

The non-statutory double patenting rejection, whether of the obviousness-type or non-obviousness-type, is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent. *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); and *In re Goodman*, 29 USPQ2d 2010 (Fed. Cir. 1993).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(b) and © may be used to overcome an actual or provisional rejection based on a non-statutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.78(d).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 56-81 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 5,468,736. Although the conflicting claims are not identical, they are not patentably distinct from each other because the dosages administered overlap.


Serial Number: 08/462,703

Page 4

Art Unit: 1205

Claims 42-107 of this application conflict with claims 42-107 of Application No. 08/462,705. 37 CFR 1.78(b) provides that when two or more applications filed by the same applicant contain conflicting claims, elimination of such claims from all but one application may be required in the absence of good and sufficient reason for their retention during pendency in more than one application. Applicant is required to either cancel the conflicting claims from all but one application or maintain a clear line of demarcation between the applications. See MPEP § 822.

Any inquiry concerning this communication should be directed to Kimberly Jordan at telephone number (703) 308-4611.


KIMBERLY JORDAN
PRIMARY EXAMINER
GROUP 1200
1610

JORDAN

June 8, 1998